Abstract Multiple sclerosis (MS) is characterized by primary inflammation, demyelination, and progressive neurodegeneration. A biochemical MS feature is neuronal mitochondrial dysfunction, compensated by anaerobic metabolism increase, likely aggravating progression of neurodegeneration. Here, we characterized a pragmatic serum profile of compounds related to mitochondrial energy metabolism of potential clinical use. Blood samples of 518 well characterized (disability, disease course) MS patients and 167 healthy controls were analyzed for serum purines, pyrimidines, creatinine, and lactate. Nine of the 15 compounds assayed, hypoxanthine, xanthine, uric acid, inosine, uracil, β-pseudouridine, uridine, creatinine, and lactate, differed significantly between MS patients and controls (p < 0.0001). Using these nine compounds, a unifying Biomarker Score was calculated. Controls and MS patients had mean Biomarker Scores of 0.4 ± 0.7 and 4.4 ± 1.9, respectively (p < 0.00001). The Biomarker Score was higher in patients with progressive (6.0 ± 1.8 than with relapsing remitting disease course (3.6 ± 1.5, p < 0.00001). High association between the Biomarker Score and increase in disability (EDSS) was also observed. Additionally, in 50 patients who underwent magnetic resonance imaging (MRI), increase in the Biomarker Score correlated to neuroanatomical alterations. These results, obtained in a large cohort of MS patients evaluated for serum metabolic compounds connected to energy metabolism, demonstrated that the Biomarker Score might represent a pragmatic, resource saving, easy to obtain, laboratory tool useful to monitor MS patients and predict at an early stage who will switch from an RR to a progressive disease course. For the first time, it was also clearly shown a link between mitochondrial dysfunction and MRI lesions characteristic of MS.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory immunemediated disease of the central nervous system (CNS) that was classically considered to leave the axons mostly undamaged at least at onset of the disease [1] 1 . Recent studies have differently demonstrated that neurodegenerative processes also 1 Patent titled BBiomarkers and methods for in vitro diagnosis of multiple sclerosis^has been filed in Rome, Italy, on the 31st of October, 2016 (no. 102016000109735).
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play a key role in the pathogenesis of MS even at early stages [2] . Due to the complexity of the pathophysiological mechanisms involved, the clinical manifestations at onset and the clinical course and progression of MS patients is heterogeneous [3] . Therefore, the heterogeneous disease course is reflected by the clinical classifications into relapsing remitting (RR), secondary progressive (SP), and primary progressive (PP). Patients with an RR disease course represent about 80 % of the total and are characterized by episodes of acute symptomatology, separated by intervals of time, of unpredictable duration, during which patients undergo to partial or full clinical recovery (remission) [4, 5] . After each relapse, patients with RR disease generally show an increase in disability and, furthermore, after 20 years, approximately 80 % of these patients convert to the SP course [6] . At that point, patients with SP disease suffer from inexorable progression of neurodegeneration causing a fast clinical deterioration with increase in disability, due to accumulation of irreversible neurologic deficits in the absence of clinical relapses [6] . PP patients, representing about 15 % of all MS patients, show a progressive clinical deterioration from the onset of the disease and, as in most SP patients, most of them lack the relapsing episodes so typical of the RR course [4, 5, 7] . The common features in MS, detectable in RR, SP, and PP, are inflammatory processes causing demyelination, progressive neuronal loss and glial scar formation, occurring in both the white and gray matter in the brain and spinal cord, either focally or diffusely [1] . The differences between those phenotypes are known to be more quantitative rather than qualitative. Thus, the RR form is characterized by a predominant pathological inflammatory pattern whereas massive neurodegenerative processes dominate the SP and PP disease courses [8] .
The aforementioned pathological hallmarks, besides changing over time, show a great variation not only between the three forms of MS but even among patients suffering from the same form of the disease, thus leading to a vast number of phenotypes and rendering very difficult to predict the disease evolution and response to therapies [9] [10] [11] .
At the molecular level, MS is characterized by various alterations including change in cellular ionic balance [12] , increased production of reactive oxygen (ROS) and nitrogen species (RNS), with consequent oxidative/nitrosative stress and induction of apoptosis [13, 14] and increase in protein misfolding [15] , with overexpression of the defensive protein Hsp 70 [16] . In common with other acute (cerebral ischemia, traumatic brain injury) and chronic neurodegenerations (Alzheimer's disease, Parkinson's disease) [17] [18] [19] , MS provokes malfunctioning of mitochondria [20] , particularly by causing decrease in the expression of most of the complexes (I, III, IV, and V) of the electron transport chain (ETC) [21] , which perturbs ATP homeostasis (unbalancing energy production and consumption) and contributes to the aforementioned biochemical alterations of important cellular functions (apoptosis, ROS and RNS production).
A significant body of literature evidenced that any time mitochondrial dysfunction and oxidative/nitrosative stress is occurring, significant changes within the interested tissue and/or in circulating compounds related to these cellular alterations can be observed. In fact, in myocardial and cerebral ischemia, it has been demonstrated the increase in both tissue and serum concentrations of purine nucleotide catabolism (hypoxanthine, xanthine, and uric acid) [22, 23] , of pyrimidine degradation [24] , of compounds representative of increased oxidative/ nitrosative stress (malondialdehyde, peroxidized fatty acids, nitric oxide metabolites) [25, 26] . Similar results have been obtained in acute (traumatic brain injury) [27] and chronic neurodegenerations [28] . Therefore, some of these metabolites has been suggested to be useful biomarkers since their determination in body fluids has been shown either to correlate with clinical symptoms, or to be predictive of insurgence of serious pathological states, or to be prognostic for patient outcome.
At present, due to the still uncertain MS etiology involving the influence of environmental factors, the individual genetic predisposition, and the immunological, biochemical, and physiological settings of the individual, there is a need for biomarkers which help to improve diagnostic and prognostic accuracy. Furthermore, notwithstanding the very many studies and the most recent findings, no reliable, easy to measure biomarkers are available to predict who of the RR patients will turn into the SP form [29, 30] . Additionally, clinicians are still searching for valuable, possibly low-cost biomarkers correlating with disability and therefore suitable to perform a frequent monitoring of the disease progression and to evaluate the efficacy of drug administration protocols.
Recently, in a large cohort of MS patients recruited at three different centers, we have found that circulating lactate is increased respectively to a group of healthy controls and, furthermore, that serum lactate concentration is correlated to the Extended Disability Status Scale scores (EDSS) and it is higher in SP and PP than in RR patients [31] . These data, corroborated by a subsequent evidence for visual pathway neurodegeneration in MS related to serum lactate increase and mitochondrial dysfunction [32] , showed that lactate seems a promising candidate biomarker for MS and supported the indication of an energy penalty in MS [33] .
The present study was undertaken to highlight in serum of MS patients a metabolic pattern of metabolites related to energy metabolism useful to evidence biomarkers related to both clinical course and disease progression. Using the same serum samples of the aforementioned cohort of MS patients [31] and the serum samples of a new group of healthy controls, we found new biomarkers, biochemically connected to energy supply and supporting the occurrence of energy impairment in MS, that were unified into a predictive Biomarker Score for MS. This Biomarker Score is characterized by a very high correlation with the disease clinical subtype, the clinical disability, the neuroanatomical lesions on magnetic resonance imaging (MRI), as well as by a simple, low-cost analytical method for quantifying biomarkers in biological fluids. Besides showing the potentially great clinical utility of the Biomarker Score, these results show, for the first time to the best of our knowledge, a close association between mitochondrial dysfunction and the cerebral tissue damages typical of MS.
Materials and Methods

Patient Population
The study was approved by the local Ethic Committees and written informed consent was obtained from all patients according to the Declaration of Helsinki.
A previously reported cohort of MS patients (n = 613) was recruited at the Institute of Neurology of the BPoliclinico Gemelli^of the Catholic University of Rome (n = 281), at the Department of Neurology, VU Medical Centre, Amsterdam, the Netherlands (n = 158) and at the Department of Neurosciences, S. Camillo-Forlanini Hospital, Rome, Italy (n = 174) [31] . Patients fulfilled the diagnostic panel criteria for MS, revised by Polman et al. [34] . They were clinically assessed using the Extended Disability Status Scale score (EDSS) [35] and included in the study only if clinically stable. Peripheral blood samples were withdrawn from each patient, who was informed about the use of the clinical data and analytical results for this research study. A clinical relapse within 1 month before withdrawal was used as an exclusion criterion.
Patients were classified into relapsing remitting (RR), secondary progressive (SP), or primary progressive (PP), according to Lublin and Reingold [36] . With respect to the previous study [31] , a new control group, consisting of 167 healthy subjects matched for age and gender, was recruited among the students of the Catholic University of Rome and the University of Catania, as well as among the personnel of these two universities who underwent the annual health check-up. Subjects suffering from any acute or chronic systemic disease, which might have influenced the serum levels of the metabolites of interests, were not included in the control group.
MRI Study
In a restricted subgroup of 50 patients, randomly selected among those recruited at the Department of Neurosciences, S. Camillo-Forlanini Hospital, Rome, Italy, MRI was carried out the same day with blood withdrawal. MRI was conducted on 1.5T system (Siemens, Magnetom) using a 32-channel head coil. Along with routine clinical MRI protocol of the brain, the following sequence was used for the analysis: sagittal 3D T1-weighted, magnetization prepared rapid gradientecho (MP-RAGE), image repetition time = 1900 ms, echo time = 3.37 ms, inversion time = 1100 ms, voxel size = 1 × 1 × 1 mm 3 , field of view 256 mm × 256 mm, 160 contiguos slices, no gap.
Brain volumes as peripheral gray matter (pgray), ventricular cerebrospinal fluid (vcsf), normalized gray matter volume (NGMV), normalized white matter volume (NWMV), and normalized brain volume (NBV), were measured on high resolution 3D T1-weighted images using SIENAX (Structural Image Evaluation using Normalization of Atrophy, Cross Sectional Method) [37] .
Preparation of Samples
In both patients and controls, peripheral venous blood samples were collected from the antecubital vein into VACUETTE® polypropylene tubes containing serum separator and clot activator (Greiner-Bio One GmbH, Kremsmunster, Austria). Blood withdrawals in both controls and MS patients were carried out after at least 15 min of complete rest. After 30 min at room temperature, samples were centrifuged at 1890×g for 10 min to separate sera and then immediately stored at −80°C until assay. To measure lactate concentration in controls, an aliquot of the 167 new control serum samples was used with no further processing.
HPLC Analysis of Metabolites
Of the original 613 serum samples of MS patients, only 518 were of sufficient volume to allow the procedure for protein removal and further analysis by high-performance liquid chromatography (HPLC). Deproteinization was performed according to a procedure described in detail [38] . Briefly, samples were first diluted with doubly-distilled water (1:2, v/v), then transferred to an Eppendorf tube equipped with a filtering membrane of 3 kDa cutoff (Nanosep® Centrifugal Devices, Pall Gelman Laboratory, Ann Harbor, MI, USA) and centrifuged at 10,500×g for 30 min at 4°C. The protein-free ultrafiltrate fluid was directly injected onto the HPLC column.
Deproteinized serum samples were loaded (200 μl) onto a Hypersil C-18, 250 × 4.6 mm, 5-μm particle size column, provided with its own guard column (ThermoElectron Italia, Rodano, Milan, Italy). The chromatographic column was connected to an HPLC apparatus consisting of a SpectraSystem P4000 pump system and a highly sensitive UV6000LP diode array detector (ThermoFisher Italia, Rodano, Milan, Italy) equipped with a 5-cm light path flow cell and covered the spectrum from 200 to 300 nm. A PC using the ChromQuest® software package, provided by the HPLC manufacturer, performed data acquisition and analysis. The synchronous determination of creatinine; purine (hypoxanthine, xanthine, adenine, uric acid, inosine, guanosine); and pyrimidine (cytosine, uracil, β-pseudouridine, thymine, cytidine, uridine, thymidine, orotic acid) profiles was performed according to an isocratic ion-pairing separation, previously set up and validated in our laboratory [38] . Assignment and calculation of the compounds of interest in chromatographic runs of biological fluid extracts were carried out at 234 nm (creatinine) or 260 nm (purine and pyrimidine compounds) wavelengths by comparing retention times, absorption spectra, and areas of peaks with those of peaks of chromatographic runs of freshly prepared ultra-pure standard mixtures with known concentrations.
Spectrophotometric Assay of Serum Lactate
The spectrophotometric determination of lactate in the 167 serum samples of the new control group was carried out using an Agilent 89090A spectrophotometer (Agilent Technologies, Santa Clara, CA, USA) and following the method described by Artiss et al. [39] .
Statistical Analysis
Statistical analysis was performed by using the Statistical Package for Social Science (SPSS), release 15.0. All data were first analyzed for normality of distribution using the Kolmogorov-Smirnov test. Continuous variables were expressed as mean ± SD, categorical variables displayed as frequencies and the appropriate parametric (Student's t test or ANOVA) or non-parametric tests (Mann-Whitney U test, Kruskal-Wallis ANOVA, χ 2 test) were used to assess significance of the differences between subgroups. A P value of less than 0.05 was considered statistically significant. Within the panel of 15 different metabolites, 9 fulfilled the characteristic of being significantly different in MS patients, when compared to the values recorded in controls. For each of these nine compounds, we determined the 95 % percentile serum concentration in control subjects. Subsequently, the entire population (controls and patients) was stratified into two categories for each biomarker: (A) Normal (0) = subjects with concentrations lower or equal to the corresponding 95 % percentile of controls and (B) Positive (1) = subjects with concentrations higher than the 95 % percentile of controls. Finally, each subject was associated to a specific biochemical pattern of markers positivity and to a BBiomarker Score^(sum of the number of positive categories), thus ranging from 0 (none of the biomarkers higher than the correspondent 95 % percentile of controls) to 9 (each biomarker higher than the correspondent 95 % percentile of controls). The schematic stepwise process to obtain the Biomarker Score starting from the analysis of selected circulating compounds representative of energy metabolism and mitochondrial dysfunction is reported in Fig. 1 .
The Biomarker Score was then used to distinguish the patients suffering from the RR form of MS from those affected by the progressive ones (SP and PP). Considering the similarities in the clinical behaviors of the progressive MS patients [5] , and the relative low To determine the association between Biomarker Scores and EDSS scores, as an index of clinical disability, a 2 × 2 table reporting the number of patients for each Biomarker Score (0 to 9) for each score of EDSS (0 to 8) was built. Subsequently, to account for the different number of patients in each EDSS class, the number of patients at each cross Biomarker Score-EDSS was multiplied by the Biomarker Score, thus obtaining a new 2 × 2 table containing the weighed Biomarker Scores, for each Biomarker Score for each EDSS.
To evaluate the relationship between the Biomarker Score and each MRI parameter of neurodegeneration, evaluated in a restricted number (n = 50) of these cohorts of MS patients, linear correlations were calculated with the Spearman correlation coefficient (ρ).
In the preliminary analysis of the data, it was determined that the dispersion of the Biomarker Score values showed a log-normal distribution in each clinical phenotype of MS patients. These normal distributions allowed to calculate the posterior probabilities for each patient to belong to a specific clinical phenotype, based on the Biomarker Score number using the Bayes theorem [40] .
Results
In Table 1 , the clinical features of MS patients and of the control group, are summarized. As it could be expected, SP and PP patients had higher EDSS scores than RR, as well as longer disease duration. No differences were observed between the groups of SP and PP. Table 2 reports the mean values and standard deviations of the nine serum metabolites (on a total of 15 metabolites quantified in each sample) that were significantly different in MS patients compared to the corresponding values recorded in controls (lactate, creatinine, and purine and pyrimidine compounds). For individual HPLC-detected purines, only hypoxanthine (Hyp), xanthine (Xan), inosine (Ino), and uric acid (UA) were significantly affected by MS with values of each compound higher than those measured in controls (p < 0.001). The most striking difference was observed for inosine, the value of which in the 167 healthy controls was 0.78 ± 0.24 μmol/l serum and in the 
Serum Metabolites in MS Patients and Controls
Serum Metabolic Profile to Distinguish Controls from MS Patients
According to what was previously described, circulating concentrations of these nine compounds in control healthy subjects were initially used to calculate the 95 % percentile, thus allowing to assign for each metabolite a 0 (concentration of a given metabolite ≤95 % percentile of controls) or a 1 metabolite score (concentration of a given metabolite >95 % percentile of controls). For each subject (controls and MS patients), a Biomarker Score was then obtained, as the sum of the metabolite scores, and ranged from 0 (each metabolite scoring 0) to 9 (each metabolite scoring 1), as summarized in the scheme reported in Fig. 1 . As illustrated in the box plot of Fig. 2 , very different values were obtained when calculating the Biomarker Scores of controls (mean ± standard deviation = 0.4 ± 0.7) and MS patients (mean ± standard deviation = 4.4 ± 1.9), i.e., MS patients (pooled cohort) had a mean Biomarker Score ten times higher than that of controls (p < 0.00001) in whom one outlier only with a Biomarker Score of 3 was observed.
The distribution frequency of Biomarker Scores of controls and MS patients is shown in Fig. 3 . A value of 0 was recorded in the 68.7 % of controls, who scored 1, 2, or 3 in the 22.7, 7.4, and 1.2 %, respectively. Conversely, more than 80 % of MS patients had a biomarker score ≥3. Table 2 where initially used to find the 95 % percentile for each metabolite in the control group. Each subject of both groups was stratified into two categories for each biomarker: (A) Negative (0) = subjects with concentration lower or equal to the corresponding 95 % percentile of controls and (B) Positive (1) = subjects with concentration higher than the 95 % percentile of controls. Each subject was then attributed with a specific biochemical pattern of markers positivity and to a BBiomarker Score^(sum of the number of positive categories), thus ranging from 0 (none of the biomarkers higher than the correspondent 95 % percentile of controls) to 9 (each biomarker higher than the correspondent 95 % percentile of controls). Asterisk significantly different from controls, p < 0.00001. Empty circle one outlier control subject, with a Biomarker Score of 3 Fig. 3 Frequency distribution of Biomarker Scores in controls (n = 167) and MS patients (n = 518). It is evident that a Biomarker Score ≥3 is found in MS patients only (only 0.6 % of controls and about 82 % of all MS patients scored ≥3) 
Serum Metabolic Profile to Distinguish RR, SP, and PP MS Disease Course
To assess whether this profile of energy-related serum metabolites, when transformed into a Biomarker Score, could distinguish relapsing remitting (RR) from the progressive (SP and PP) disease course, MS patients were categorized into RR (n = 360), SP (n = 132), and PP (n = 26) and Biomarker Scores were matched accordingly. As illustrated in the box plot of Fig. 4 , RR, SP, and PP patients had mean Biomarker Scores, respectively, of 3.6 ± 1.5, 6.0 ± 1.8, and 5.9 ± 1.7 (p < 0.00001 compared to controls). Two outliers only, one in the group of RR (0.28 %, patient scoring 9) and one in the group of PP patients (3.8 %, patient scoring 2), were recorded. A comparison of the Biomarker Scores among the three groups of MS patients revealed that RR had Biomarker Scores lower than those scored by patients affected by either one of the progressive forms of MS (p < 0.00001). The comparison of the Biomarker Scores between the progressive forms of MS failed to show any statistical significance.
In Fig. 5a -c, the frequency distribution of Biomarker Score in different multiple sclerosis clinical subtypes is reported. As shown in Fig. 5a , a substantial overlapping in the biomarker score frequency distribution between the SP and PP classes was observed. As indicated in Fig. 5b, c , the RR were distinguished from the SP + PP group for a Biomarker Score ≥6, since only the 10, 1.1, 0.6, and 0.3 % of the RR patients scored 6, 7, 8, or 9, respectively. The probability to fall into controls, RR, or SP + PP groups, according to the Biomarker Score value and using the Bayes theorem, is shown in Fig. 6 . From these three curves, it is evident that a Biomarker Score ≥3 or 4 is highly associated to MS with only an 8 and 3 % probability, respectively, that this serum metabolic pattern is found in a control healthy subject. Furthermore, for these values of the Biomarker Score, MS patients can be classified, almost exclusively, into RR (only 3 and 24 % probability that a Biomarker Score of 3 and 4 is associated to an SP + PP patient, respectively), while higher values of the Biomarker Score are typical of MS patients suffering from the progressive form of the disease.
Association of Serum Metabolic Profiles of MS Patients with Clinical Disability
A mean value of the weighed Biomarker Score of 0.4 ± 0.04, calculated as described in section BMaterials and Methods,^was observed for controls. As shown in Fig. 7 , when plotting the weighed Biomarker Score of the MS patients as a function of the EDSS score, a linear dependence starting from 2.3 up to 7.7 was observed, strongly indicating that the increase of disability is accompanied by a deterioration of the serum metabolic patterns of the metabolites under valuation, clearly related to the patients' Biomarker Score.
Association of Serum Metabolic Profiles of MS Patients with MRI
The group of 50 patients (34 females (F), 16 males (M)), who underwent MRI analysis, aged 41.57 ± 8.84 years, had a mean EDSS of 1.99 ± 1.89, and were 46 RR and 4 PP. Mean values of pgray, vcsf, NGMV, NWMV, and NBV were 601.39 ± 49.12, 52.55 ± 22.64, 762.08 ± 62.44, 708.35 ± 59.06, and 1.482.93 ± 123.14, respectively. The statistical analysis evidenced that the Biomarker Score correlates with the main parameters of neurodegeneration that can be determined by MRI. In particular, pgray had a ρ = −0.360 (p < 0.01), vcsf had a ρ = 0.367 (p < 0.01), NGMV had a ρ = −0.369 (p < 0.007), NWMV had a ρ = −0.258 (p < 0.07), and NBV had a ρ = −0.313 (p < 0.05). That is, only the value of white matter did not reach the statistical significance, certainly because of the limited number of patients who underwent MRI analysis.
Discussion
The first important remark that can be obtained from the results reported in the present study is that MS is characterized by dysfunctional metabolic cycles and pathways related to energy metabolism, leading to significant changes in the serum profiles of compounds directly (purines) or indirectly (creatinine, lactate, and pyrimidines) connected to ATP homeostasis and indicating an impairment of cellular energy supply [41, 42] . Since cellular energy imbalance occurs when energy production does not compensate for energy consumption and since mitochondria are the main source of ATP Fig. 6 Probability curves of Biomarker Scores of controls, RR, and SP + PP MS patients. The curves were calculated as described in BMaterials and Methods^(statistical analyses) Fig. 7 Linear correlation between Biomarker Score and EDSS score, as a clinical parameter to evaluate disability in MS patients. As indicated by the high value of the correlation coefficient, the circulating biochemical pattern, described by the Biomarker Score and reflecting cellular energy metabolism state, are strongly associated with MS disability production, our results strongly corroborate the Bmitochondrial hypothesis^involved in MS progression [20, 31, 43, 44] , even though from these data it is not possible to exclude the contribution of tissue source other than the brain in the overall serum increase of these metabolic signatures of cell dysfunctional mitochondria. However, several recent studies emphasized that in both active and inactive lesions, as well as in normal-appearing white matter, there are unequivocal molecular indicators (expression of glycolytic enzymes, glucose and monocarboxylate transporters, regulators of mitochondrial functions, etc.) showing that cerebral cells (neurons, astrocytes, glial cells) of MS patients suffer from impairment in energy metabolism [31-33, 41, 45] . In addition, the recent studies showing that ETC complexes, including ATP synthase, are quite abundantly located in the myelin sheath contributing to significant production of extramitochondrial ATP [46] [47] [48] , further substantiate the notion that MS patients, typically affected by a myelin disease, are characterized by chronic energy penalty.
Therefore, the increase in circulating values of lactate; creatinine; purines (hypoxanthine, xanthine, uric acid, and inosine); and pyrimidines (uracil, β-pseudouridine, and uridine) recorded in the serum samples of our cohort of 518 MS patients, should in large part be due to the cerebral cell chronic insufficiency to provide ATP concentrations, via mitochondrial oxidative phosphorylation, in such an amount to support adequate energy requirements. Consequently, as illustrated in the scheme of Fig. 8 , (i) on one side, the adaptive cellular mechanisms tend to compensate the reduced mitochondrial functions associated to MS by increasing the rate of glycolysis and the quote of glycolytically produced ATP, therefore leading to sustained higher rates of the glycolytic flux resulting in increased lactate formation [31, 32, 49] ; (ii) on the other side, the imbalance in ATP production and consumption is translated into an increased rate of the purine catabolic pathway, with consequent increase of dephosphorylated purine endproducts (hypoxanthine, xanthine, uric acid, and inosine). Circulating levels of these metabolites, including lactate, significantly increase in MS patients, forming the signature of neuronal dysfunctional mitochondria and representing the basis for the quantification of the Biomarker Score correlating with MS course and disability (Fig. 8) .
Referring to (i), as previously reported [31] , our cohort of MS patients had about three times higher serum lactate than the value measured in controls (Table 2) , thus corroborating the indications of occurrence of dysfunctional glucose metabolism in MS [41, 45, 50] . As far as (ii) is concerned, we found that serum samples of MS patients had various indicators of purine catabolism higher than those of controls. Particularly, inosine, hypoxanthine, xanthine, and uric acid, sequentially positioned in the purine catabolic cascade, increased by 6.3, 2.4, 2.5, and 1.35 times, respectively, greatly contributing to the demonstration of the energy imbalance associated with MS. As previously observed in the plasma [33, 51] and CSF [42] of two independent cohorts of MS patients, we again found that circulating concentrations of uric acid in MS undergo to significant increase, in contrast to the various studies reporting that MS causes a decrease in the serum/plasma values of uric acid [52] [53] [54] [55] . While most of these studies did not very frequently provide either an adequate number of patients, or an adequate control group, or an evaluation of the full profile of purines, our data have been obtained in a very large sample size, with control values recorded in a group of age and sex-matched healthy subjects, and reporting values for the full purine profile determined with a highly suitable, reproducible, and sensitive HPLC method [38] . It is worthwhile mentioning that, even in the case of Alzheimer's disease (AD), serum uric acid was found decreased by the pathology [56] [57] [58] and this finding was claimed as a clear indication of the importance of this compound as a tissue antioxidant; however, additional studies reported totally opposite results showing that uric acid is higher in AD and demented patients [59] [60] [61] [62] and suggesting that its circulating elevation is not strictly a signature of increased oxidative stress but mostly of energy metabolism dysregulation [63] . These conclusions are in agreement with the cellular levels of the different low Fig. 8 Schematic representation of the interconnections among mitochondrial dysfunction, circulating values of energyrelated metabolites and the Biomarker Score in MS molecular weight antioxidants which, particularly in the brain, are largely composed by ascorbic acid [64] , glutathione [64] , carnosine [65] and are at hundred folds higher concentrations than uric acid [66, 67] . Therefore, taken together with the other circulating purines, uric acid in serum/plasma represents a biochemical index of altered energy metabolism mainly associated with mitochondrial dysfunction [68] , as also clearly illustrated by exhaustive reviews on the clinical biochemical meaning of the analysis of serum uric acid [63, 69] . Since uridine has been indicated as an indirect index of imbalanced ATP homeostasis [24, 70] , the 1.9 times higher serum uridine than controls, recorded in our cohort of MS patients, is a further support to the general energy dysmetabolism characterizing MS pathobiology. Differently, the increase in the serum values of the two other pyrimidines measured in this study (uracil and β-pseudouridine) should reflect an increased rate in RNA turnover, particularly of transfer RNA (tRNA) where β-pseudouridine is one of the most abundant modified bases [71] .
Since none of the compounds of interest is of exquisite cerebral origin, and since MS patients are at risk of a number of intercurrent systemic inflammatory or non-inflammatory conditions [72, 73] , it cannot be excluded a significant extracerebral contribution in the overall serum increase of the aforementioned metabolites. In addition, the muscular involvement in MS [74, 75] possibly caused by a metabolic imbalance of myocytes and also evidenced by an increased cost of walking in patients with mild disability [76] , might further contribute to exacerbate alterations in the serum metabolic profile of MS patients.
Although the aforementioned information contributes to a better comprehension of the pathological mechanisms of MS affecting the cellular energy metabolism, the second most relevant information of the present study is that profiling of the circulating concentrations of these compounds is capable either to discriminate controls from MS patients, or most importantly, to distinguish the RR from the progressive patient's group, or to evaluate the increase in MS disability. According to our statistical approach, this panel of nine metabolites, most of them directly or indirectly connected with cell energy metabolism, allow to obtain a Biomarker Score index (from 0 to 9) that clearly discriminates control healthy subjects from MS patients, and is a valuable predictor of the irreversible transition from an RR to a SP disease course. In fact, from the data shown in Figs. 4 and 5, it is possible to clearly observe that the subgroup of RR patients had a frequency distribution of the Biomarker Score very different from that of the MS patients with progressive disease course. Furthermore, according to the data illustrated in Fig. 6 , the determination of this Biomarker Score allowed to calculate the probability curves for the two subgroups of RR and progressive patients (as well as for controls) that can be highly useful to monitor the disease progression and to modulate the consequent pharmacological treatment protocols. In fact, if in the follow up of an RR MS patient the Biomarker Score is maintained between 2 and 4 (i.e., only two to four of the metabolites determined in serum had values higher than the 95 % percentile of controls) there is a low probability of an RR → SP transition and the drug administration protocol (type of drug and dosage) is satisfactorily counteracting the disease progression. Differently, an RR MS patient showing an increase in the Biomarker Score at values higher than 4 will gradually increase his probability that the disease will convert into a progressive SP form, that is the drug administration protocol should be modulated accordingly to reduce the risk of conversion from an RR → to a SP disease course.
Notwithstanding MRI results were only available from a limited number of patients, the magnitude of the findings implies that reproducibility can readily be tested in a better powered MRI-based MS cohort. This will be highly relevant to validate the here proposed Biomarker Score as a useful compound marker for neurodegeneration in MS. These findings are even more important since this is the first time, to the best of our knowledge, that circulating low molecular weight compounds related to the cell energy metabolism are significantly associated with well-established anatomical indexes used to grade MS [37] , i.e., parameters of mitochondrial dysfunction, through the use of the Biomarker Score, are directly linked to cerebral tissue damages characteristic of MS.
This information deriving from the Biomarker Score determination might also be used to monitor the increase in the clinical disability in the follow up of MS patients. The results illustrated in Fig. 7 , indicating a linear correlation between the Biomarker Score and the EDSS score, indicate that MS disability is associated with a given metabolic feature subjected to change upon worsening of the patient's conditions. It is presumable that indexing the Biomarker Score, since molecular events precedes changes in the clinical manifestations, might be predictive of future changes in clinical disability of a given patient. Again, this type of information is essential to drive drug administration protocols. Potentially, it is conceivable that the Biomarker Score is a useful tool to perform a personalized therapy for each MS patient who will be treated not only based on the gross clinical information, but also on his impairment of cell energy metabolism, as determined by the panel of metabolites measured in his serum and unified into a Biomarker Score.
Several recent studies proposed a number of new potential biomarkers detectable in blood samples of MS patients [3, 29, 30] . One of them has been conducted longitudinally in a relatively low number of subjects and proposing the use of NMR, a technique definitely infrequent in the clinical biochemical laboratories, to screen for serum metabolite patterns associated with disease progression [77] . The other recent longitudinal study has been carried out in a larger group of MS patients and proposing a panel of genetic, immunological, inflammatory, and biochemical parameters (oxidative stressrelated) correlated with progression and disability of MS [78] . The disadvantage of the proposed panel of parameters to evaluate MS is that it is time consuming (5-6 different types of analyses must be performed) and characterized by elevated analytical costs. Moreover, it is highly probable that some of the techniques needed to measure some of the proposed parameters (lipid hydroperoxides, carbonylated proteins, advanced oxidation protein products, TNFβ NcoI polymorphism) are not frequently encountered in the routine of the clinical biochemical laboratory hospitals.
With respect to these [77, 78] and other studies [79] [80] [81] [82] , the present results have the great advantage to have been obtained by applying a simple, low-cost, reliable, and easy to perform analytical method, capable to separate and quantify in one single shot of about 30 min, 8/9 parameters suitable to obtain the proposed Biomarker Score. The analysis requires the use of an HPLC instrumentation present nearly in any private and public clinical biochemical laboratory (lactate, the ninth metabolic parameter included in the calculation of the Biomarker Score, is routinely assayed in any laboratory at very low cost).
The present results demonstrated that the Biomarker Score, calculated by determining the circulating levels of lactate; creatinine; purines (hypoxanthine, xanthine, uric acid, and inosine); and pyrimidines (uracil, β-pseudouridine, and uridine), might represent a promising laboratory tool useful as a secondary outcome for treatment trials aimed to prevent the transition from RR to SP. Although obtained in one of the largest cohorts of MS patients evaluated for their specific serum metabolic profile, additional studies are needed to clarify whether this Biomarker Score is of diagnostic utility to predict at an early stage who will switch from a relapsing remitting to a progressive disease course.
Limitations of the Study
The major limitation of this study is that MS patients were not longitudinally assayed, thereby lacking a clear-cut evidence linking the increase of the Biomarker Score with the worsening of the patient clinical state, i.e., the correlation with the disease progression and disability is only statistical and obtained on groups formed by different patients.
A second possible limitation is that the selected analytical approach did not take into account parameters related to inflammation/immunology. One of our goal was to supply a tool of significant clinical utility adoptable by a large number of centers due to the aforementioned analytical characteristics. It is certainly true that our results included only biochemical parameters of metabolism; however, these compounds have benefit to represent different pathways directly or indirectly connected to cell energy homeostasis, with some of them positioned at different steps of the same metabolic cascade. In our opinion, this biochemical homogeneity strongly reinforces the validity of the calculated Biomarker Score and increases its significance in the pathobiological mechanisms of MS progression.
